Senate Biologics Bill Draws Industry Ire
Bipartisan legislation introduced in the U.S. Senate that would create a regulatory process for the U.S. Food and Drug Administration to approve generic versions of biologic drugs is being lambasted by...To view the full article, register now.
Already a subscriber? Click here to view full article